Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.31 is 118% above its 5-year average of -1.71, around the middle of its 5-year range (-9.07–7.80).
As of the fiscal period ended Tuesday, June 30, 2026. 112.94% above its 12-month average of -2.42.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.31.
DEBT TO EQUITY RATIO
0.31
DEBT TO EQUITY RATIO AVG TTM
-2.42
DEBT TO EQUITY RATIO AVG 3Y
-4.32
DEBT TO EQUITY RATIO AVG 5Y
-1.71
DEBT TO EQUITY RATIO AVG 10Y
0.05
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+112.94%
CURRENT VS 3Y AVG
+107.25%
CURRENT VS 5Y AVG
+118.36%
CURRENT VS 10Y AVG
+561.40%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.18
median of 313 covered companies
CURRENT VS SECTOR MEDIAN
+74.06%
vs the sector median at left
Ascendis Pharma A/S
Market Cap
$14.16B
Debt to Equity Ratio
0.31
TTM Avg
-2.42
3Y Avg
-4.32
5Y Avg
-1.71
Market Cap
$14.97B
Debt to Equity Ratio
1.07
TTM Avg
0.88
3Y Avg
0.91
5Y Avg
0.99
Market Cap
$13.19B
Debt to Equity Ratio
0.01
TTM Avg
0.01
3Y Avg
0.01
5Y Avg
0.00
Market Cap
$15.24B
Debt to Equity Ratio
1.10
TTM Avg
1.85
3Y Avg
1.11
5Y Avg
0.89
Market Cap
$12.95B
Debt to Equity Ratio
N/A
TTM Avg
4.39
3Y Avg
4.39
5Y Avg
4.39
Market Cap
$12.89B
Debt to Equity Ratio
0.37
TTM Avg
0.39
3Y Avg
0.44
5Y Avg
0.45
Market Cap
$12.52B
Debt to Equity Ratio
1.56
TTM Avg
1.78
3Y Avg
2.05
5Y Avg
1.83
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ascendis Pharma A/S (ASND) | $14.16B | 0.31 | -2.42 | -4.32 | -1.71 |
| Tempus AI, Inc. (TEM)vs › | $14.64B | 3.25 | 5.51 | 5.51 | 5.51 |
| Exelixis, Inc. (EXEL)vs › | $14.79B | 0.09 | 0.08 | 0.08 | 0.07 |
| Charles River Laboratories International, Inc. (CRL)vs › | $14.97B | 1.07 | 0.88 | 0.91 | 0.99 |
| Corcept Therapeutics Incorporated (CORT)vs › | $13.19B | 0.01 | 0.01 | 0.01 | 0.00 |
| Solventum Corporation (SOLV)vs › | $15.24B | 1.10 | 1.85 | 1.11 | 0.89 |
| BridgeBio Pharma, Inc. (BBIO)vs › | $12.95B | N/A | 4.39 | 4.39 | 4.39 |
| ICON Public Limited Company (ICLR)vs › | $12.89B | 0.37 | 0.39 | 0.44 | 0.45 |
| Baxter International Inc. (BAX)vs › | $12.52B | 1.56 | 1.78 | 2.05 | 1.83 |
| Penumbra, Inc. (PEN)vs › | $12.49B | 0.14 | 0.17 | 0.20 | 0.18 |
Debt/Equity
0.31
Current Ratio
2.99
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.31 |
| 2026-03-31 | 1.84 |
| 2025-12-31 | -5.35 |
| 2025-09-30 | -4.67 |
| 2025-06-30 | -4.23 |
| 2025-03-31 | -4.46 |
| 2024-12-31 | -8.10 |
| 2024-09-30 | -8.10 |
| 2024-06-30 | -2.09 |
| 2024-03-31 | -2.81 |
| 2023-12-31 | -5.10 |
| 2023-09-30 | -9.07 |
| 2023-06-30 | 7.80 |
| 2023-03-31 | 3.02 |
| 2022-12-31 | 1.93 |
| 2022-09-30 | 1.23 |
| 2022-06-30 | 0.84 |
| 2022-03-31 | 0.70 |
| 2021-12-31 | 0.24 |
| 2021-09-30 | 0.10 |
| 2021-06-30 | 0.15 |
| 2021-03-31 | 0.12 |
| 2020-12-31 | 0.11 |
| 2020-09-30 | 0.03 |
| 2020-06-30 | 0.07 |
| 2020-03-31 | 0.07 |
| 2019-12-31 | 0.06 |
| 2019-09-30 | 0.06 |
| 2019-06-30 | 0.05 |
| 2019-03-31 | 0.02 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
| 2013-09-30 | 0.00 |
| 2013-06-30 | 0.00 |
| 2013-03-31 | 0.00 |
